Télécharger le texte intégral - ISPED-Enseignement à distance

177
81. Eastman PS, Shapiro DE, Coombs RW, Frenkel LM, McSherry GD, Britto P, et al. Maternal
viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent
perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical
Trials Group Protocol 076. J Infect Dis 1998;177(3):557-564.
82. Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, et al.
Selection and fading of resistance mutations in women and infants receiving nevirapine to
prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001;15(15):1951-7.
83. Cunningham CK, Chaix ML, Rekacewicz C, Britto P, Rouzioux C, Gelber RD, et al.
Development of resistance mutations in women receiving standard antiretroviral therapy who
received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1
transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis
2002;186(2):181-8.
84. Eshleman SH, Becker-Pergola G, Deseyve M, Guay LA, Mracna M, Fleming T, et al. Impact
of human immunodeficiency virus type 1 (hiv-1) subtype on women receiving single-dose
nevirapine prophylaxis to prevent hiv-1 vertical transmission (HIV network for prevention
trials 012 study). J Infect Dis 2001;184(7):914-917.
85. Beckerman KP. Long-term findings of HIVNET 012: the next steps. Lancet
2003;362(9387):842-843.
86. Morris L, Pillay C, Chezzi C, Lupondwana P, Ntsala M, Levin L, et al. Low frequency of the
V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine.
AIDS 2003;17(11):1698-1700.
87. Giuliano M, Palmisano L, Galluzzo CM, Amici R, Germinario E, Okong P, et al. Selection of
resistance mutations in pregnant women receiving zidovudine and lamivudine to prevent HIV
perinatal transmission. AIDS 2003;17(10):1570-1572.
88. Biggar RJ, Miotti PG, Taha TE, Mtimavalye L, Broadhead R, Justesen A, et al. Perinatal
intervention trial in Africa: effect of a birth canal cleansing intervention to prevent HIV
transmission. Lancet 1996;347(9016):1647-1650.
89. Msellati P, Meda N, Leroy V, Likikouet R, Van de Perre P, Cartoux M, et al. Safety and
acceptability of vaginal disinfection with benzalkonium chloride in HIV infected pregnant
women in west Africa: ANRS 049b phase II randomized, double blinded placebo controlled
trial. DITRAME Study Group. Sex Transm Infect 1999;75(6):420-425.
90. Mandelbrot L, Msellati P, Meda N, Leroy V, Likikouet R, VandePerre P, et al. 15 Month
follow up of African children following vaginal cleansing with benzalkonium chloride of their
HIV infected mothers during late pregnancy and delivery. Sex Transm Infect 2002;78(4):267-
270.
91. Gaillard P, Mwanyumba F, Verhofstede C, Claeys P, Chohan V, Goetghebeur E, et al. Vaginal
lavage with chlorhexidine during labour to reduce mother-to-child HIV transmission: clinical
trial in Mombasa, Kenya. AIDS 2001;15(3):389-96.
92. Taha TE, Biggar RJ, Broadhead RL, Mtimavalye LA, Justesen AB, Liomba GN, et al. Effect
of cleansing the birth canal with antiseptic solution on maternal and newborn morbidity and
mortality in Malawi: clinical trial. BMJ 1997;315(7102):216-219.
93. Fawzi WW, Msamanga GI, Spiegelman D, Urassa EJ, Hunter DJ. Rationale and design of the
Tanzania Vitamin and HIV Infection Trial. Control Clin Trials 1999;20(1):75-90.